{
  "id": 20948514,
  "title": "Kymera to announce phase 2b atopic dermatitis trial results Monday",
  "url": "https://urgent.news/2026/11/20/kymera-to-announce-phase-2b-atopic-dermatitis-trial-results-monday",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-20T21:04:31.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/kymera-to-announce-phase-2b-atopic-dermatitis-trial-results-monday-93CH-5042603"
  },
  "original_language": "en",
  "account": "WATERTOWN, Massachusetts - Kymera Therapeutics is set to reveal the Phase 2b clinical trial outcomes for its oral STAT6 degrader, KT-621, on Monday, November 23, 2026, according to a press release. The study assessed the investigational drug's efficacy in patients suffering from moderate to severe atopic dermatitis. Kymera, a biopharmaceutical company based in Massachusetts, aims to issue a press release at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET. The drug, known as a first-in-class, once-daily oral degrader of STAT6, targets IL-4/IL-13 signaling pathways. Kymera, established in 2016, is dedicated to creating oral small molecule degrader medicines for immunological conditions.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Celldex Ends Barzolvolimab Development In Atopic Dermatitis After Phase 2 Trial Misses Key Endpoints",
        "url": "https://urgent.news/2026/11/20/celldex-ends-barzolvolimab-development-in-atopic-dermatitis-after",
        "published": "2026-11-20T06:10:37.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}